WO2003002713A3 - Antibodies to opgl - Google Patents

Antibodies to opgl Download PDF

Info

Publication number
WO2003002713A3
WO2003002713A3 PCT/US2002/020181 US0220181W WO03002713A3 WO 2003002713 A3 WO2003002713 A3 WO 2003002713A3 US 0220181 W US0220181 W US 0220181W WO 03002713 A3 WO03002713 A3 WO 03002713A3
Authority
WO
WIPO (PCT)
Prior art keywords
opgl
antibodies
methods
amount
administering
Prior art date
Application number
PCT/US2002/020181
Other languages
French (fr)
Other versions
WO2003002713A2 (en
Inventor
William J Boyle
Francis H Martin
Jose R Corvalan
Geoffrey C Davis
Original Assignee
Abgenix Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003002713(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MEP-2008-326A priority Critical patent/ME00232B/en
Priority to DK02749660.3T priority patent/DK1409016T4/en
Priority to EA200400063A priority patent/EA021242B9/en
Priority to JP2003509075A priority patent/JP4212470B2/en
Priority to KR10-2003-7017009A priority patent/KR20040023630A/en
Priority to EP10185344.8A priority patent/EP2295081B1/en
Priority to CA2451955A priority patent/CA2451955C/en
Priority to MXPA04000134A priority patent/MXPA04000134A/en
Priority to BRPI0210579-9 priority patent/BRPI0210579B8/en
Priority to ES02749660T priority patent/ES2342820T5/en
Priority to NZ530765A priority patent/NZ530765A/en
Priority to AU2002320157A priority patent/AU2002320157C1/en
Priority to DE60235989T priority patent/DE60235989D1/en
Priority to MEP-326/08A priority patent/MEP32608A/en
Priority to EP18202340.8A priority patent/EP3492100B1/en
Application filed by Abgenix Inc, Amgen Inc filed Critical Abgenix Inc
Priority to IL15951202A priority patent/IL159512A0/en
Priority to AT02749660T priority patent/ATE464068T1/en
Priority to NO20200535A priority patent/NO345566B1/en
Priority to EP02749660.3A priority patent/EP1409016B9/en
Publication of WO2003002713A2 publication Critical patent/WO2003002713A2/en
Publication of WO2003002713A3 publication Critical patent/WO2003002713A3/en
Priority to IL159512A priority patent/IL159512A/en
Priority to NO20041018A priority patent/NO343687B1/en
Priority to AU2008261137A priority patent/AU2008261137C1/en
Priority to CY20101100637T priority patent/CY1110196T1/en
Priority to CY2010016C priority patent/CY2010016I2/en
Priority to LU91757C priority patent/LU91757I2/en
Priority to FR10C0050C priority patent/FR10C0050I2/en
Priority to IL235116A priority patent/IL235116A0/en
Priority to CY20191100079T priority patent/CY1121151T1/en
Priority to NO20190456A priority patent/NO344842B1/en
Priority to NO2019039C priority patent/NO2019039I1/en
Priority to NO2019048C priority patent/NO2019048I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
PCT/US2002/020181 2001-06-26 2002-06-25 Antibodies to opgl WO2003002713A2 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
EP02749660.3A EP1409016B9 (en) 2001-06-26 2002-06-25 Antibodies to opgl
AT02749660T ATE464068T1 (en) 2001-06-26 2002-06-25 ANTIBODIES AGAINST OPGL
EA200400063A EA021242B9 (en) 2001-06-26 2002-06-25 Antibodies to osteoprotegerin ligand (opgl)
JP2003509075A JP4212470B2 (en) 2001-06-26 2002-06-25 Antibody to OPGL
IL15951202A IL159512A0 (en) 2001-06-26 2002-06-25 Antibodies to opgl
EP10185344.8A EP2295081B1 (en) 2001-06-26 2002-06-25 Antibodies to OPGL
CA2451955A CA2451955C (en) 2001-06-26 2002-06-25 Antibodies to opgl
DK02749660.3T DK1409016T4 (en) 2001-06-26 2002-06-25 Antibodies to OPGL
BRPI0210579-9 BRPI0210579B8 (en) 2001-06-26 2002-06-25 antibody and pharmaceutical composition
NO20200535A NO345566B1 (en) 2001-06-26 2002-06-25 OPGL binding antibody, pharmaceutical composition and use
NZ530765A NZ530765A (en) 2001-06-26 2002-06-25 Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
AU2002320157A AU2002320157C1 (en) 2001-06-26 2002-06-25 Antibodies to OPGL
DE60235989T DE60235989D1 (en) 2001-06-26 2002-06-25 ANTIBODIES AGAINST OPGL
MEP-326/08A MEP32608A (en) 2001-06-26 2002-06-25 Antibodies to opgl
EP18202340.8A EP3492100B1 (en) 2001-06-26 2002-06-25 Antibodies to opgl
MEP-2008-326A ME00232B (en) 2001-06-26 2002-06-25 Antibodies to opgl
KR10-2003-7017009A KR20040023630A (en) 2001-06-26 2002-06-25 Antibodies to opgl
MXPA04000134A MXPA04000134A (en) 2001-06-26 2002-06-25 Antibodies to opgl.
ES02749660T ES2342820T5 (en) 2001-06-26 2002-06-25 OPGL antibodies
IL159512A IL159512A (en) 2001-06-26 2003-12-22 Antibodies that bind osteoprotegerin ligand
NO20041018A NO343687B1 (en) 2001-06-26 2004-03-10 OPGL binding antibody and pharmaceutical composition thereof
AU2008261137A AU2008261137C1 (en) 2001-06-26 2008-12-19 Antibodies to OPGL
CY20101100637T CY1110196T1 (en) 2001-06-26 2010-07-08 ANTIBODIES TO OSTEOPRETEGERIN LINDING MOLECULE (OPGL)
CY2010016C CY2010016I2 (en) 2001-06-26 2010-11-24 ANTIBODIES TO OSTEOPRETEGERIN LINDING MOLECULE (OPGL)
LU91757C LU91757I2 (en) 2001-06-26 2010-11-24 Denosumab and its pharmaceutically acceptable derivatives (PROLIA®)
FR10C0050C FR10C0050I2 (en) 2001-06-26 2010-11-25 OPGL ANTIBODIES
IL235116A IL235116A0 (en) 2001-06-26 2014-10-19 Antibodies to opgl
CY20191100079T CY1121151T1 (en) 2001-06-26 2019-01-21 ANTIBODIES TO OPGL
NO20190456A NO344842B1 (en) 2001-06-26 2019-04-04 OPGL binding antibody, polynucleotide composition, host cell, pharmaceutical composition and use and preparation of the antibody
NO2019039C NO2019039I1 (en) 2001-06-26 2019-11-05 Denosumab
NO2019048C NO2019048I1 (en) 2001-06-26 2019-12-20 Denosumab

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30117201P 2001-06-26 2001-06-26
US60/301,172 2001-06-26

Publications (2)

Publication Number Publication Date
WO2003002713A2 WO2003002713A2 (en) 2003-01-09
WO2003002713A3 true WO2003002713A3 (en) 2003-08-14

Family

ID=23162250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020181 WO2003002713A2 (en) 2001-06-26 2002-06-25 Antibodies to opgl

Country Status (33)

Country Link
US (8) US7364736B2 (en)
EP (5) EP2270052B8 (en)
JP (13) JP4212470B2 (en)
KR (2) KR101038585B1 (en)
CN (2) CN103232539B (en)
AR (1) AR034637A1 (en)
AT (1) ATE464068T1 (en)
AU (2) AU2002320157C1 (en)
BR (1) BRPI0210579B8 (en)
CA (1) CA2451955C (en)
CY (5) CY1110196T1 (en)
DE (2) DE122010000047I1 (en)
DK (4) DK2270052T3 (en)
EA (1) EA021242B9 (en)
ES (5) ES2674888T3 (en)
FR (1) FR10C0050I2 (en)
HK (1) HK1187932A1 (en)
IL (3) IL159512A0 (en)
LU (1) LU91757I2 (en)
ME (2) MEP32608A (en)
MX (1) MXPA04000134A (en)
MY (1) MY143582A (en)
NO (5) NO345566B1 (en)
NZ (4) NZ547695A (en)
PL (1) PL222211B1 (en)
PT (4) PT2087908T (en)
RS (1) RS54274B1 (en)
SG (3) SG173211A1 (en)
TR (3) TR201809008T4 (en)
TW (2) TWI326285B (en)
WO (1) WO2003002713A2 (en)
YU (1) YU103003A (en)
ZA (1) ZA200400521B (en)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP4138013B2 (en) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ligand for receptor activator of NF-KAPPA B, a member of TNF superfamily
JP3523650B2 (en) * 1997-04-15 2004-04-26 三共株式会社 Novel protein and method for producing the same
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL132304A0 (en) 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
PT2009025E (en) 1998-05-14 2011-09-19 Immunex Corp Method of inhibiting osteoclast activity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US6884598B2 (en) 2000-09-22 2005-04-26 Immunex Corporation Screening assays for agonists and antagonists of receptor activator of NF-κB
ME00502B (en) 2001-01-05 2011-10-10 Amgen Fremont Inc Antibodies to insulin-like growth factor i receptor
TR201809008T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
JP5525118B2 (en) 2002-09-11 2014-06-18 中外製薬株式会社 Protein purification method
ATE458006T1 (en) * 2003-05-14 2010-03-15 Kenta Biotech Ag HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO LIPOPOLYSACCHARIDES (LPS) OF SEROTYPE IATS O6 OF PSEUDOMONAS AERUGINOSA
BR0318454A (en) 2003-08-08 2006-09-12 Abgenix Inc parathyroid hormone (pth) targeting antibodies and their uses
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
ME01198B (en) * 2003-11-05 2013-03-20 Ares Trading Sa Process for the purification of il-18 binding protein
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US20060115901A1 (en) * 2004-10-22 2006-06-01 Bahram Valamehr Method and media for single cell serum-free culture of CHO cells
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
WO2006110277A1 (en) * 2005-04-11 2006-10-19 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
AU2015242973C1 (en) * 2005-06-14 2018-07-05 Amgen Inc. Self-buffering protein formulations
SG162788A1 (en) * 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
JP2009502972A (en) * 2005-07-29 2009-01-29 アムジエン・インコーポレーテツド Formulation that suppresses protein aggregation
TW200736277A (en) * 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (en) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN THE BONE MODELING PROCESS
WO2007125605A1 (en) * 2006-04-28 2007-11-08 Kyoritsu Seiyaku Corporation Feline cell capable of being cultured without animal protein, and method for production of virus and method for production of vaccine using the feline cell
UA99262C2 (en) 2006-08-28 2012-08-10 Арес Трейдінг С.А. Process for reducing the concentration of free fc-moieties in a fluid comprising an fc-containing protein
BRPI0809112A2 (en) * 2007-03-22 2014-08-26 Imclone Llc STABLE ANTIBODY FORMULATIONS
CN101796072B (en) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 Amino acid sequences directed against RANK-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
JP5963341B2 (en) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド Homogeneous antibody population
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
DK2206727T3 (en) 2007-10-11 2015-07-06 Daiichi Sankyo Co Ltd ANTIBODY SPECIFIC TO OSTEOKLASTRELATERET PROTEIN Siglec-15
ES2962777T3 (en) 2007-11-15 2024-03-21 Amgen Inc Antioxidant-stabilized aqueous antibody formulation for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP5431361B2 (en) 2008-01-09 2014-03-05 セルカ ゲーエムベーハー Improved culture medium additive and method of using the same
WO2009099641A2 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
AR073072A1 (en) 2008-08-19 2010-10-13 Regeneron Pharma HUMAN ANTIBODIES FOR THE BINDING OF THE HUMAN NF-KB RECEIVER ACTIVATOR (RANKL)
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
AU2010235453B2 (en) 2009-04-09 2013-10-03 Daiichi Sankyo Company,Limited Anti-Siglec-15 antibody
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
US9629881B2 (en) 2010-02-01 2017-04-25 Rebiotix, Inc. Bacteriotherapy for clostridium difficile colitis
US9061097B2 (en) 2010-06-07 2015-06-23 Amgen Inc. Drug delivery device
JP5699030B2 (en) * 2010-07-05 2015-04-08 Ａｘｉｓ株式会社 A therapeutic agent for fibromyalgia containing etanercept
EP2625205A2 (en) 2010-10-05 2013-08-14 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
KR102240323B1 (en) 2010-10-06 2021-04-14 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
MX341790B (en) 2011-03-31 2016-09-02 Amgen Inc Vial adapter and system.
CA2833748C (en) 2011-04-20 2019-07-16 Amgen Inc. Autoinjector apparatus
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
ES2729993T3 (en) 2011-10-14 2019-11-07 Amgen Inc Injector and assembly procedure
CN107233569B (en) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 Antibody formulations and methods
WO2013118878A1 (en) * 2012-02-09 2013-08-15 独立行政法人理化学研究所 Cyclic rna and protein production method
SG11201405966PA (en) 2012-03-30 2014-11-27 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9695244B2 (en) * 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
DK2859120T3 (en) 2012-06-06 2019-01-14 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
ES2723885T3 (en) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anti-Siglec-15 antibodies
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
TW202042841A (en) 2012-09-07 2020-12-01 美商柯赫勒斯生物科學有限公司 Stable aqueous formulations of adalimumab
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CN104995313A (en) 2012-10-12 2015-10-21 生物运动有限公司 Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using C-MAF
EP2922590B1 (en) 2012-11-21 2020-02-05 Amgen Inc. Drug delivery device
WO2014115022A1 (en) 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
TWI580451B (en) 2013-03-15 2017-05-01 安美基公司 Cassette for an injector and method of using an autoinjector apparatus having an autoinjector and a cassette
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
LT2976117T (en) 2013-03-22 2021-02-25 Amgen Inc. Injector and method of assembly
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CA2914636C (en) 2013-06-05 2021-04-06 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
WO2015047994A2 (en) * 2013-09-24 2015-04-02 The Board Of Regentsl Of The University Of Texas System A novel hormone that promotes bone resorption and uses thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
AU2014340171B2 (en) 2013-10-24 2019-05-30 Amgen Inc. Injector and method of assembly
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
AU2013408259B2 (en) * 2013-12-20 2020-05-21 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
CN103965357B (en) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 A kind of anti-human RANKL antibody
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
JP6293907B2 (en) 2014-03-10 2018-03-14 リヒター ゲデオン エヌワイアールティー． Purification of immunoglobulin using pre-cleaning process
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
JP6817074B2 (en) 2014-06-03 2021-01-20 アムジエン・インコーポレーテツド Controllable drug delivery system and usage
PT3152317T (en) * 2014-06-04 2019-04-18 Amgen Inc Methods for harvesting mammalian cell cultures
MX2021014323A (en) 2014-10-14 2023-02-02 Amgen Inc Drug injection device with visual and audio indicators.
JP2017538412A (en) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． Binding member for human C-MAF
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3233163B1 (en) 2014-12-19 2021-10-13 Amgen Inc. Drug delivery device with proximity sensor
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US10328123B2 (en) 2015-02-25 2019-06-25 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
US10111928B1 (en) * 2015-02-25 2018-10-30 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta
US10745461B2 (en) 2015-02-25 2020-08-18 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
BR112017023233A2 (en) 2015-04-29 2018-11-06 Radius Pharmaceuticals Inc methods for cancer treatment
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PL3307289T3 (en) 2015-06-09 2022-01-17 Rebiotix, Inc. Methods of manufacture of microbiota restoration therapy (mrt) compositions
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
HU231463B1 (en) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Method for increasing the galactose content of recombinant proteins
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
JP7082568B2 (en) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
AU2017229575A1 (en) 2016-03-08 2018-09-27 Janssen Biotech, Inc. GITR antibodies, methods, and uses
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
KR102571924B1 (en) 2016-05-25 2023-08-28 인바이오모션 에스.엘. Treatment of breast cancer based on c-MAF status
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
CN109982685B (en) 2016-10-21 2022-03-11 美国安进公司 Pharmaceutical formulations and process for their preparation
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018205285C1 (en) 2017-01-05 2023-08-24 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
MX2019009625A (en) 2017-02-17 2019-10-09 Amgen Inc Drug delivery device with sterile fluid flowpath and related method of assembly.
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
IL303449B1 (en) 2017-03-09 2024-04-01 Amgen Inc Insertion mechanism for drug delivery device
CN114588404A (en) 2017-03-28 2022-06-07 美国安进公司 Plunger rod and syringe assembly systems and methods
JOP20190255A1 (en) 2017-04-28 2019-10-27 Amgen Inc Formulations of human anti-rankl antibodies, and methods of using the same
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
MX2019015479A (en) 2017-06-23 2020-02-20 Amgen Inc Electronic drug delivery device comprising a cap activated by a switch assembly.
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
JP2020527376A (en) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド Gas permeable sealing material and assembly method for drug containers
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
JP7242562B2 (en) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド Drug delivery device with container access system and associated method of assembly
MA49838A (en) 2017-08-09 2020-06-17 Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50553A (en) 2017-11-06 2020-09-16 Amgen Inc DRUG ADMINISTRATION DEVICE WITH POSITIONING AND FLOW DETECTION
MA50569A (en) 2017-11-06 2020-09-16 Amgen Inc FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
JP7247174B2 (en) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド plunger for drug delivery device
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
MA50903A (en) 2017-11-16 2021-05-12 Amgen Inc SELF-INJECTOR WITH STALL AND END POINT DETECTION
KR20200104298A (en) 2017-11-22 2020-09-03 인바이오모션 에스.엘. Therapeutic treatment of breast cancer based on c-MAF status
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3104395A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MA53375A (en) 2018-07-24 2021-06-02 Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (en) 2018-07-31 2021-11-03 Amgen Inc FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (en) 2018-10-02 2021-06-02 Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH INTERNAL FORCE TRANSMISSION
US20210338936A1 (en) 2018-10-05 2021-11-04 Amgen Inc. Drug delivery device having dose indicator
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
EP3866890A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Drug delivery device having damping mechanism
EP3873567A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial needle retraction
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
HUP1800376A2 (en) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
HUP1900112A1 (en) 2019-04-04 2020-10-28 Richter Gedeon Nyrt Improvement of affinity chromatography of immunoglobulins by using pre-capture flocculation
MX2021012557A (en) 2019-04-24 2021-11-12 Amgen Inc Syringe sterilization verification assemblies and methods.
MX2021013271A (en) 2019-04-30 2022-01-06 Inst De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors.
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
CN113621060B (en) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 OPG antibody pair and application thereof
CA3217207A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2024064878A1 (en) 2022-09-23 2024-03-28 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886152A (en) * 1991-12-06 1999-03-23 Sumitomo Pharmaceuticals Company, Limited Humanized B-B10
US5891438A (en) * 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
WO2000037504A2 (en) * 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US20020015055A1 (en) * 2000-07-18 2002-02-07 Silicon Graphics, Inc. Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5900400A (en) 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US4760130A (en) 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
JPS6291197A (en) 1985-10-17 1987-04-25 Dainippon Pharmaceut Co Ltd Anti-human interleukin 1 antibody, its production and use thereof
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
DK590387A (en) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd ANTIBODIES AGAINST INTERLEUKIN-1
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
EP0364778B1 (en) 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
FR2640146B1 (en) 1988-12-08 1993-12-24 Commissariat A Energie Atomique ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES 1 (ALPHA) AND 1 (BETA), THEIR PRODUCTION METHOD AND APPLICATIONS OF SAID ANTIBODIES TO DETECTION OF INTERLEUKINS 1 (ALPHA) AND 1 (BETA) AND THERAPEUTICS
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2238070T3 (en) 1989-04-21 2005-08-16 Amgen Inc. TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE.
DE3922089A1 (en) 1989-05-09 1990-12-13 Basf Ag NEW PROTEINS AND THEIR PRODUCTION
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL107267A (en) 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ATE194384T1 (en) 1989-09-12 2000-07-15 Hoffmann La Roche TNF-BINDING PROTEINS
JPH03127800A (en) 1989-10-13 1991-05-30 Teijin Ltd Tumor necrosis factor activity inhibitor
CA2068320C (en) 1989-11-29 2000-10-17 Robert Hageman Production of recombinant human interleukin-1 inhibitor
JPH0578396A (en) 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd Human tumor necrosis factor-bineding protein
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
AU649245B2 (en) 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
US5872095A (en) 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
JPH05506986A (en) 1990-05-01 1993-10-14 カイロン　コーポレイション Interleukin-1 antagonist and its use
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
EP0464533B1 (en) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionproteins with parts of immunoglobulins, their production and use
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
JPH06500078A (en) 1990-08-03 1994-01-06 スミスクライン・ビーチャム・コーポレイション TNF inhibitor
US5840496A (en) 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
NZ241311A (en) 1991-01-17 1995-03-28 Gen Hospital Corp Rna sequence having trans-splicing activity, plant strains
JP2864434B2 (en) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド Methods of treating tumor necrosis factor-mediated diseases
CA2288429C (en) 1991-03-15 2006-04-25 Synergen, Inc. Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0611302B1 (en) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
ES2038546B1 (en) 1991-11-08 1994-02-16 Andromaco Lab PROCEDURE FOR OBTAINING A PRODUCT OF A POLYPEPTIDIC NATURE WITH INHIBITING ACTIVITY OF THE HYPERPRODUCTION OF THE TUMOR NECROSIS FACTOR.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
ATE230990T1 (en) 1992-03-04 2003-02-15 Cell Therapeutics Inc ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS
ATE242322T1 (en) 1992-03-30 2003-06-15 Immunex Corp FUSION PROTEIN CONTAINING TWO TUMOR NECROSIS FACTOR RECEPTORS
DK0639079T3 (en) 1992-04-30 2000-06-13 Amgen Inc Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases
JPH05312248A (en) 1992-05-08 1993-11-22 Nissan Motor Co Ltd Shift level device
DE4219626A1 (en) 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Incorporating therapeutic gene via vector into body cells - in=vivo or in vitro, for subsequent expression and secretion of active protein, partic. for treating degenerative diseases of spine and nerves
JPH0630788A (en) 1992-07-16 1994-02-08 Otsuka Pharmaceut Co Ltd Recombinant antibody for human interleukin-1
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
DE69333378T2 (en) 1992-09-17 2004-07-01 Amgen Inc., Thousand Oaks PHARMACEUTICAL COMPOSITIONS WITH INTERLEUKIN-1 INHIBITORS
JPH06111399A (en) 1992-09-30 1994-04-22 Sony Corp Magneto-optical recording medium and its production
US5646154A (en) 1992-10-07 1997-07-08 Sumitomo Pharmaceuticals Co., Ltd. Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
US5866576A (en) 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
DK0607776T3 (en) 1993-01-08 1999-08-16 Hoechst Ag Use of leflunomide to inhibit tumor necrosis factor alpha
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
CA2157782A1 (en) 1993-03-08 1994-09-15 Joseph C. Glorioso Gene transfer for treating a connective tissue of a mammalian host
AU6285694A (en) 1993-03-19 1994-10-11 Vacsyn S.A. Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US5843905A (en) 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE69430747T2 (en) 1993-07-28 2003-03-06 Aventis Pharma Ltd CONNECTIONS AS PDE IV AND TNF INHIBITORS
DE69416859T2 (en) 1993-11-29 1999-08-05 Merrell Pharma Inc BENZOLSULFONYLIMINE DERIVATIVES AS INHIBITORS OF THE IL-1 EFFECT
CA2138305A1 (en) 1993-12-28 1995-06-29 Naohito Ohashi Tumor necrosis factor production inhibitors
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
EP0749428B1 (en) 1994-03-09 1998-07-29 Pfizer Inc. Isoxazoline compounds as inhibitors of tnf release
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5817822A (en) 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
IL114417A0 (en) 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
US5641747A (en) 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
IT1269989B (en) 1994-09-21 1997-04-16 Dompe Spa IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY
PL183510B1 (en) 1994-10-05 2002-06-28 Darwin Discovery Ltd Peptide compounds and their therapeutic application as inhibitors
US5852173A (en) 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
ZA9510826B (en) 1994-12-23 1996-06-20 Smithkline Beecham Corp 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
EP0796096A4 (en) 1994-12-23 1998-04-29 Smithkline Beecham Corp 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5886010A (en) 1995-01-09 1999-03-23 Otsuka Pharmaceutical Company, Limited TNF-αinhibitor
PE64396A1 (en) 1995-01-23 1997-01-28 Hoffmann La Roche INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN
DE69607750T2 (en) 1995-02-23 2000-08-31 Novartis Nutrition Ag AMINO ACID COMPOSITIONS AND USE OF THE SAME CLINICAL FOOD
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
EP0737471A3 (en) 1995-04-10 2000-12-06 L'oreal Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2217850A1 (en) 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
AR004471A1 (en) 1995-05-31 1998-12-16 Smithkline Beecham Corp CYCLOHEXAN-1-OL-4,4-DISSTITUTED COMPOUNDS, USEFUL IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5817476A (en) 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US5830742A (en) 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
WO1997001633A1 (en) 1995-06-29 1997-01-16 Immunex Corporation Cytokine that induces apoptosis
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
WO1997012244A1 (en) 1995-09-27 1997-04-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining t-cell profiles of immunocompromised subjects
PL185312B1 (en) 1995-10-05 2003-04-30 Darwin Discovery Ltd Thio-substituted peptides as inhibitors of metal proteinases and thf liberation
DE19540475A1 (en) 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
IL124366A0 (en) 1995-11-14 1998-12-06 Du Pont Merck Pharma Novel macrocyclic compounds as metalloprotease inhibitors
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CO4750805A1 (en) * 1995-12-13 1999-03-31 Sumitomo Chemical Co SHAMPOO COMPOUND
US5869315A (en) 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
US5891883A (en) 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US5990119A (en) 1995-12-21 1999-11-23 Smithkline Beecham Corporation 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
US5869677A (en) 1995-12-21 1999-02-09 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
EP0870028A1 (en) 1995-12-29 1998-10-14 Incyte Pharmaceuticals, Inc. Nucleic acids encoding interferon gamma inducing factor-2
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
IL125552A0 (en) 1996-02-09 1999-03-12 Amgen Inc Composition comprising interleukin-1 inhibitor and controlled release polymer
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
US5994351A (en) 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US5981220A (en) 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
GB9607249D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
GB9609795D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
AUPO048296A0 (en) 1996-06-14 1996-07-11 Fujisawa Pharmaceutical Co., Ltd. New compound and its preparation
EP0816499A3 (en) 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
DE69700616T2 (en) 1996-07-02 2000-03-16 Nisshin Flour Milling Co Imide derivatives
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
JPH10130149A (en) 1996-07-12 1998-05-19 Sankyo Co Ltd Tnf production inhibitor
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
KR100539031B1 (en) 1996-08-12 2005-12-27 셀진 코포레이션 Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
ES2217428T3 (en) 1996-09-25 2004-11-01 Ss Pharmaceutical Co., Ltd. VINILPIRIDINE DERIVATIVES REPLACED AND MEDICINES CONTAINING THEM
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9621859D0 (en) 1996-10-21 1996-12-11 Xenova Ltd Cytokine production inhibitors
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
JPH10147531A (en) 1996-11-19 1998-06-02 Otsuka Pharmaceut Co Ltd Tnf-alpha production inhibitor
US5955480A (en) 1996-11-20 1999-09-21 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
CA2271963A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5834435A (en) 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DE19652227A1 (en) 1996-12-16 1998-06-18 Bosch Gmbh Robert Method and device for assigning a remote control to a base station
JPH10231285A (en) 1996-12-17 1998-09-02 Ishihara Sangyo Kaisha Ltd Phthalimide derivative or its salt, their production and pharmaceutical composition containing the derivative
JP4138013B2 (en) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ligand for receptor activator of NF-KAPPA B, a member of TNF superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
PT853083E (en) 1997-01-06 2001-12-28 Pfizer COMPOSITION OF PYRIDILFURANE AND PYRIDYLTHOPHENE AND ITS PHARMACEUTICAL UTILIZATION
ZA9818B (en) 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5952320A (en) 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
BR9714328A (en) 1997-01-29 2000-03-21 Pfizer of interleukin-1 activity
JP3955352B2 (en) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 Osteoclast formation inhibitor
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
EP0984959B1 (en) 1997-03-04 2003-09-24 Pharmacia Corporation Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6451791B1 (en) 1997-03-04 2002-09-17 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JPH10259140A (en) 1997-03-18 1998-09-29 Sumitomo Pharmaceut Co Ltd Tumor necrotizing factor production inhibitor
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
AU6769298A (en) 1997-03-21 1998-10-20 Cistron Biotechnology, Inc. Method for inhibiting cleavage of precursor il-1beta
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US6251913B1 (en) 1997-03-28 2001-06-26 Zeneca Limited Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
US6242615B1 (en) 1997-03-28 2001-06-05 Zeneca Limited Process for the preparation of N-(3-hydroxy-succinyl)-amino acid derivatives
US6117654A (en) 1997-08-04 2000-09-12 Millennium Biotherapeutics, Inc. Nucleic acid molecules encoding Tango-77-polypeptides
US6380218B1 (en) 1997-04-04 2002-04-30 Pfizer Inc Nicotinamide derivatives
ES2245028T3 (en) 1997-04-10 2005-12-16 Agennix, Inc. USE OF LACTOFERRIN IN THE TREATMENT OF DISORDERS INDICATED BY ALLERGENS
JP3523650B2 (en) 1997-04-15 2004-04-26 三共株式会社 Novel protein and method for producing the same
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL132304A0 (en) * 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
FR2762315B1 (en) 1997-04-22 1999-05-28 Logeais Labor Jacques AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE
PT1028954E (en) 1997-04-24 2003-11-28 Ortho Mcneil Pharm Inc IMIDAZOLES SUBSTITUIDOS UTEIS IN THE TREATMENT OF INFLAMMATORY DISEASES
FR2762514B1 (en) 1997-04-29 1999-10-22 Sanofi Sa USE OF TETRAHYDROPYRIDINE DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES LEADING TO DEMYELINATION
JP3776203B2 (en) 1997-05-13 2006-05-17 第一製薬株式会社 ICAM-1 production inhibitor
BR9809451A (en) 1997-05-22 2000-06-20 Searle & Co Pyrazoles substituted with 3 (5) -heteroaryl as inhibitors of p38 kinase.
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
JPH111481A (en) 1997-06-10 1999-01-06 Sumitomo Pharmaceut Co Ltd Piperidinylphthalazine derivative
RU2221795C2 (en) 1997-06-12 2004-01-20 Авентис Фарма Лимитед Imidazolyl-cyclic acetals, intermediate compounds, pharmaceutical composition and treatment method
KR19990001101A (en) 1997-06-12 1999-01-15 손경식 Catechol amino acid derivatives, preparation methods thereof and pharmaceutical compositions containing the same
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp Novel pyrazole and pyrazoline substituted compounds
GB9713732D0 (en) 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Substituted triazinic compounds
GB9713733D0 (en) 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Poly-branched polycarboxamido compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6235787B1 (en) 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
US5843721A (en) 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
AU8858398A (en) 1997-07-10 1999-02-08 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
DE19731521A1 (en) 1997-07-23 1999-01-28 Byk Gulden Lomberg Chem Fab Budipin in the treatment of inflammatory diseases of the nervous system
FR2766822B1 (en) 1997-07-30 2001-02-23 Adir NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR016551A1 (en) 1997-07-30 2001-07-25 Smithkline Beecham Corp DERIVATIVES OF 2-OXINDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
TR200000221T2 (en) 1997-07-31 2000-09-21 Celgene Corporation Modified alkanohydroxamic acids and TNF alpha reduction method.
EP1003751A1 (en) 1997-08-04 2000-05-31 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
KR20000068711A (en) 1997-08-06 2000-11-25 도리이 신이치로 1-Aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
PT895988E (en) 1997-08-08 2002-09-30 Pfizer Prod Inc ARYLSULPHONYLAMINO-HYDROXAMIC ACID DERIVATIVES
WO1999007679A1 (en) 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
EP1007038A2 (en) 1997-08-21 2000-06-14 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
AU751524B2 (en) 1997-11-03 2002-08-22 Trustees Of The University Of Pennsylvania, The Method and compositions for inhibiting angiogenesis and treating cancer
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
EP1047683A1 (en) 1998-01-16 2000-11-02 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
ATE232536T1 (en) 1998-01-20 2003-02-15 Warner Lambert Co N-(2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-
NZ505880A (en) 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides
EP1049777B1 (en) 1998-01-23 2005-08-03 Immunex Corporation Acpl dna and polypeptides
JP2002528046A (en) 1998-01-27 2002-09-03 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド Novel receptor superfamily molecules and their uses
IL137162A0 (en) 1998-01-27 2001-07-24 American Cyanamid Co 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
AU2901899A (en) 1998-03-09 1999-09-27 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CN1297354A (en) 1998-03-16 2001-05-30 西托维亚公司 Dipeptide caspase inhibitors and use thereof
IL126024A0 (en) 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
NZ528282A (en) 1998-03-19 2005-05-27 Vertex Pharma Interleukin-1 beta converting enzyme inhibitors
DE69929877T2 (en) 1998-03-20 2006-08-10 Daiichi Asubio Pharma Co., Ltd. BENZOCHINONE DERIVATIVES INHIBITORS OF NF-kB
CA2325741C (en) 1998-03-26 2007-05-08 Santen Pharmaceutical Co., Ltd. Urea derivatives having tnf- .alpha. production inhibitory effects
PT2009025E (en) 1998-05-14 2011-09-19 Immunex Corp Method of inhibiting osteoclast activity
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
BR9816013A (en) 1998-09-01 2003-01-21 Hayashibara Biochem Lab Interleukin-18 Binding Protein
CA2343654A1 (en) * 1998-09-15 2000-03-23 M&E Biotech A/S Method for down-regulating osteoprotegerin ligand activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
SI1149114T1 (en) 1999-02-03 2014-08-29 Amgen Inc. Polypeptides involved in immune response
WO2000047740A2 (en) 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
AR026946A1 (en) 1999-12-16 2003-03-05 Amgen Inc OSTEOPROTEGERINE / TUMOR NECROSIS FACTORS RECEPTORS
AU3868001A (en) † 2000-02-23 2001-09-03 Amgen Inc Antagonistic selective binding agents of osteoprotegerin binding protein
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US7102050B1 (en) 2000-05-04 2006-09-05 Exxonmobil Chemical Patents Inc. Multiple riser reactor
JP2003534022A (en) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Anti-RANK ligand monoclonal antibodies useful for treating RANK ligand mediated disorders
DE10039710B4 (en) 2000-08-14 2017-06-22 United Monolithic Semiconductors Gmbh Method for producing passive components on a semiconductor substrate
US20040247596A1 (en) * 2000-08-18 2004-12-09 Odgren Paul R. TRANCE regulation of chondrocyte differentiation
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ME00502B (en) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antibodies to insulin-like growth factor i receptor
WO2002092016A2 (en) 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
US20030021785A1 (en) 2001-06-06 2003-01-30 Dougall William C. Use of rank antagonists to treat cancer
TR201809008T4 (en) * 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2013180295A1 (en) 2012-06-01 2013-12-05 日本電信電話株式会社 Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886152A (en) * 1991-12-06 1999-03-23 Sumitomo Pharmaceuticals Company, Limited Humanized B-B10
US5891438A (en) * 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
WO2000037504A2 (en) * 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US20020015055A1 (en) * 2000-07-18 2002-02-07 Silicon Graphics, Inc. Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units

Also Published As

Publication number Publication date
CY1120658T1 (en) 2019-12-11
MY143582A (en) 2011-05-31
ES2675735T3 (en) 2018-07-12
US20200131271A1 (en) 2020-04-30
JP5576903B2 (en) 2014-08-20
TW200630107A (en) 2006-09-01
BR0210579A (en) 2005-05-10
ES2674888T3 (en) 2018-07-04
US20090274688A1 (en) 2009-11-05
ES2907826T3 (en) 2022-04-26
CA2451955A1 (en) 2003-01-09
KR20100041797A (en) 2010-04-22
AR034637A1 (en) 2004-03-03
CY1110196T1 (en) 2012-01-25
EP2295081A1 (en) 2011-03-16
JP2009273466A (en) 2009-11-26
NZ530765A (en) 2006-11-30
DK2295081T3 (en) 2019-02-18
DK2087908T3 (en) 2018-07-23
EP1409016A2 (en) 2004-04-21
US20040033535A1 (en) 2004-02-19
EP2087908B1 (en) 2018-05-30
AU2008261137B2 (en) 2012-10-04
AU2002320157B2 (en) 2008-10-16
NZ547695A (en) 2008-09-26
ES2706902T3 (en) 2019-04-01
JP2022000424A (en) 2022-01-04
NO2019048I1 (en) 2019-12-20
JP2015078205A (en) 2015-04-23
EP2270052A2 (en) 2011-01-05
MXPA04000134A (en) 2005-06-06
JP4927910B2 (en) 2012-05-09
NO345566B1 (en) 2021-04-19
PT2087908T (en) 2018-07-16
WO2003002713A2 (en) 2003-01-09
US20200354464A1 (en) 2020-11-12
TR201900581T4 (en) 2019-02-21
ES2342820T5 (en) 2021-04-14
JP4212470B2 (en) 2009-01-21
JP2015057408A (en) 2015-03-26
HK1187932A1 (en) 2014-04-17
IL159512A (en) 2014-12-31
CY1121151T1 (en) 2020-05-29
NZ616594A (en) 2015-06-26
US20140134157A1 (en) 2014-05-15
EP2295081B1 (en) 2018-10-31
YU103003A (en) 2006-05-25
NO343687B1 (en) 2019-05-06
AU2008261137A1 (en) 2009-01-15
JP2012229236A (en) 2012-11-22
NZ581637A (en) 2012-05-25
FR10C0050I1 (en) 2011-01-14
LU91757I9 (en) 2019-01-03
EP2270052B8 (en) 2018-05-02
EA021242B9 (en) 2015-11-30
EA200400063A1 (en) 2005-02-24
EP1409016B2 (en) 2020-07-15
NO344842B1 (en) 2020-05-25
CA2451955C (en) 2015-09-29
SG2011076551A (en) 2015-08-28
AU2008261137C1 (en) 2023-08-31
EP3492100B1 (en) 2021-12-08
RS20120347A3 (en) 2013-10-31
ME00232B (en) 2011-02-10
EP3492100A1 (en) 2019-06-05
EP1409016A4 (en) 2005-11-09
SG173211A1 (en) 2011-08-29
US20120087923A1 (en) 2012-04-12
JP2005506963A (en) 2005-03-10
NO20200535A1 (en) 2004-03-10
TWI326285B (en) 2010-06-21
EP2087908A1 (en) 2009-08-12
EP1409016B9 (en) 2020-10-28
JP2020073518A (en) 2020-05-14
IL159512A0 (en) 2004-06-01
US7364736B2 (en) 2008-04-29
IL235116A0 (en) 2014-11-30
EP1409016B1 (en) 2010-04-14
PL222211B1 (en) 2016-07-29
US8058418B2 (en) 2011-11-15
TR201809008T4 (en) 2018-07-23
PT1409016E (en) 2010-06-11
US20150266952A1 (en) 2015-09-24
MEP32608A (en) 2011-02-10
CY1120656T1 (en) 2019-12-11
KR20040023630A (en) 2004-03-18
JP2019214563A (en) 2019-12-19
JP4358282B2 (en) 2009-11-04
NO20190456A1 (en) 2004-03-10
US20170183417A1 (en) 2017-06-29
EA021242B1 (en) 2015-05-29
JP2016216464A (en) 2016-12-22
FR10C0050I2 (en) 2011-12-30
KR101038585B1 (en) 2011-06-03
JP2012153701A (en) 2012-08-16
LU91757I2 (en) 2011-01-24
CN1547486A (en) 2004-11-17
AU2002320157C1 (en) 2023-09-21
CN103232539B (en) 2015-06-03
EP2270052A3 (en) 2011-03-02
TR201809678T4 (en) 2018-07-23
ZA200400521B (en) 2005-07-27
DK1409016T3 (en) 2010-06-21
RS54274B1 (en) 2016-02-29
TWI276443B (en) 2007-03-21
PL371915A1 (en) 2005-07-11
JP2018154614A (en) 2018-10-04
SG10201603108QA (en) 2016-05-30
DK2270052T3 (en) 2018-07-02
ES2342820T3 (en) 2010-07-15
NO20041018L (en) 2004-03-10
CY2010016I1 (en) 2012-01-25
DE60235989D1 (en) 2010-05-27
BRPI0210579B8 (en) 2021-05-25
DK1409016T4 (en) 2020-09-14
DE122010000047I1 (en) 2011-05-05
EP2270052B1 (en) 2018-03-28
ATE464068T1 (en) 2010-04-15
RS20120347A2 (en) 2013-04-30
PT2270052T (en) 2018-07-04
US8409578B2 (en) 2013-04-02
JP2012140430A (en) 2012-07-26
BRPI0210579B1 (en) 2019-05-14
CY2010016I2 (en) 2012-01-25
CN103232539A (en) 2013-08-07
JP2009022280A (en) 2009-02-05
PT2295081T (en) 2019-02-01
JP5065529B2 (en) 2012-11-07
NO2019039I1 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
WO2003002713A3 (en) Antibodies to opgl
WO2003086289A3 (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2004022718A3 (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
WO2001051924A3 (en) Method for determining the response to cancer therapy
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2005044792A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2002000653A3 (en) Fused cyclic compounds as modulators of nuclear hormone receptor function
AU2001264172A1 (en) Methods and compositions for diagnosing chronic immune disease
AU4445201A (en) Method for administering insulin to the buccal region
WO2008060466A3 (en) Individualized dosage determination for local administration of therapeutic particles
AU2999801A (en) A method for detecting the reactivity of lymphocyte in blood to a specific antigen
WO2008013935A3 (en) Tyrosine phosphorylation sites
시몬 Copyright (C) 2003 NuriMedia Co., Ltd.
AU2002304743A1 (en) Cancer treatment by using fap-alpha specific antibodies
AU2002243311A1 (en) Immunoassay technique using multispecific molecules

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-1030/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159512

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501360

Country of ref document: PH

Ref document number: 2451955

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003509075

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037017009

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000134

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002320157

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200400063

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002749660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 530765

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20028166809

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002749660

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1020107002067

Country of ref document: KR